Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;36 Suppl 2(Suppl 2):S155-61.
doi: 10.2337/dcS13-2031.

Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013

Guntram Schernthaner  1 , Craig J Currie, Gerit-Holger Schernthaner
Affiliations

Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013

Guntram Schernthaner et al. Diabetes Care. 2013 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Protection effects of pioglitazone relating to various organs.
See this image and copyright information in PMC

References

    1. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008;31:714–719 - PubMed
    1. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet [corrected] Study Group Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068–6076 - PubMed
    1. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093–1104 - PubMed
    1. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. DURATION-4 Study Group Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252–258 - PMC - PubMed
    1. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70:1945–1961 - PubMed

MeSH terms